Heat Biologics Inc (NASDAQ:HTBX) a clinical stage biopharmaceutical company developing cancer immunotherapies and OncoSec Medical Inc (OTCMKTS:ONCS) a firm working on development of “DNA-based” intratumoral cancer immunotherapies said that they finalized an agreement to assess the combination of the immunotherapy developed by each company.
Under the agreement, Heat and OncoSec will jointly examine the preclinical effectiveness of OncoSec’s core technology known as ImmunoPulse with Heat’s gp-96-Ig supported ImPACT immunotherapy platform. ImmunoPulse is an investigational phase intratumoral DNA delivery offering. Taylor Schreiber, MD, Phd who is the VP of R&D with Heat said that the management is excited to start the collaboration with OncoSec. The later company is one of the pioneers in the segment of intratumoral DNA delivery. The deal with OncoSec reflects Heat’s desire to expand its ImPACT system into DNA-based immunotherapies to fuel immunity to both private and shared tumor antigens without resulting in the complexities related with personalized therapies.
The management view
Robert H. Pierce, MD, OncoSec’s CSO said that in this deal the management will assess the effectiveness of Heat’s proprietary DNA creates with the company’s clinical stage electroporation system. The ImPACT platform is an innovative approach that particularly stimulates tumor specific cytotoxic T-cells. The expert team anticipates that it will be successful with OncoSec’s intratumoral delivery system that has already witnessed encouraging clinical activity in both distant and local tumors in patients suffering with metastatic melanoma.
Heat and OncoSec are exploring the deal as part of their strategy to expand the use of their proprietary technologies to benefit cancer patients. OncoSec’s core offering, ImmunoPulse, is supported by the intratumoral delivery of “DNA IL-12.” it is in Phase 2 clinical trials, examining the approach for cure of metastatic melanoma cutaneous T-cell lymphoma, head and neck cancer and triple negative breast cancer. The combination if succeeds can result in effective treatment in the future.